BETHLEHEM, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended December 31, 2024.
"Our Q4 revenue was consistent with our expectations, including 10% growth in our core revenue. We continue to see signs of gradual recovery in our key end markets, and we are diversifying our business by expanding our product portfolio and adding new customers, offset by elevated uncertainty for some of our existing customers related to government funding sources," said OraSure President and CEO Carrie Eglinton Manner. "We made tremendous progress in our strategic transformation in 2024, which gives us confidence that OTI is positioned to deliver growth in our core business and drive further productivity gains."
She added, "Our strong balance sheet has allowed us to significantly advance our innovation strategy, including the acquisition of Sherlock Biosciences, which brings to our pipeline an advanced molecular platform that we expect will expand access to diagnostic insights through convenient, effortless tests. Overall, we continue to progress operationally to leverage our differentiated products and our strong customer relationships to drive profitable long-term growth and create shareholder value."
Financial Highlights
For the Three Months Ended December 31,
For the Years Ended December 31,
2024
2023
% Change
2024
2023
% Change
Core Business (1)
$
36,482
$
33,310
10
%
$
138,950
$
143,219
(3)%
Molecular Services
13
907
(99
)
1,705
4,474
(62
)
COVID-19
950
41,664
(98
)
45,172
257,779
(82
)
Total Net Revenues
$
37,445
$
75,881
(51)%
$
185,827
$
405,472
(54)%
(1) Includes Diagnostics, Sample Management Solutions, Risk Assessment Testing, other products and services revenues, and non-product and services revenues.
For the Three Months Ended December 31,
For the Years Ended December 31,
2024
2023
% Change
2024
2023
% Change
Net revenues
$
37,445
$
75,881
(51)%
$
185,827
$
405,472
(54)%
Gross profit
13,566
35,126
(61
)
79,390
171,652
(54
)
Gross margin
36.2
%
46.3
%
42.7
%
42.3
%
Non-GAAP gross profit
15,000
35,264
(57
)
82,490
173,262
(52
)
Non-GAAP gross margin
40.1
%
46.5
%
44.4
%
42.7
%
Operating income (loss)
(12,418
)
3,898
NM
(28,250
)
32,684
NM
Operating margin
(33.2)%
5.1
%
(15.2)%
8.1
%
Non-GAAP operating income (loss)
(6,745
)
11,151
NM
(6,422
)
62,350
NM
Non-GAAP operating margin
(18.0)%
14.7
%
(3.5)%
15.4
%
Net income (loss)
(10,794
)
20,073
NM
(19,500
)
53,655
NM
Non-GAAP net income (loss)
(4,230
)
13,521
NM
3,943
66,311
(94
)
Diluted GAAP EPS
$
(0.14
)
$
0.27
NM
$
(0.26
)
$
0.72
NM
Diluted Non-GAAP EPS
$
(0.06
)
$
0.18
NM
$
0.05
$
0.89
(94
)
NM – not meaningful
Total net revenues for the fourth quarter of 2024 decreased 51% to $37.4 million from $75.9 million in the fourth quarter of 2023 primarily due to the decline in COVID-19 revenues.
Core revenues (all revenues excluding COVID-19 and Molecular Services revenues) of $36.5 million in the fourth quarter increased 10% year-over-year. Diagnostics revenues in the fourth quarter increased 9% year-over-year to $18.8 million and Sample Management Solutions revenues increased 14% to $14.8 million.
COVID-19 revenues of $1.0 million in the fourth quarter decreased 98% year-over-year primarily due to the completion of our largest government contract earlier in 2024.
GAAP gross margin was 36.2% in the fourth quarter of 2024 compared to 46.3% in the fourth quarter of 2023. Non-GAAP gross margin in the fourth quarter of 2024 was 40.1% compared to 46.5% in the fourth quarter of 20231. On a year-over-year basis, gross margin was impacted by the decline in COVID-19 revenues and the higher mix of international revenues.
GAAP operating loss in the fourth quarter of 2024 was $12.4 million compared to operating income of $3.9 million in the fourth quarter of 2023. Non-GAAP operating loss was $6.7 million in the fourth quarter of 2024 compared to non-GAAP operating income of $11.2 million in the fourth quarter of 2023.
Cash and cash equivalents were $267.8 million as of December 31, 2024. Cash flow from operations in the fourth quarter of 2024 was $0.1 million. During the fourth quarter, we deployed $5.0 million for the acquisition of Sherlock Biosciences.
1 For additional information on non-GAAP financial measures and a reconciliation of the GAAP financial results to non-GAAP financial results, see the schedules below. A description of the adjustments made to the GAAP financial measures is included at the end of the schedules.
Recent Business Developments
OTI acquired Sherlock Biosciences in December to expand our innovation pipeline with the addition of a molecular diagnostics platform that, subject to approval by the U.S. Food and Drug Administration (FDA), is expected to provide rapid results with strong sensitivity and specificity in a disposable format that will be well-suited for over-the-counter usage. Sherlock's first molecular self-test, for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG), is in clinical trials and is expected to be submitted to the FDA by the end of 2025 for review.
Received FDA approval for a labeling change to the OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents. The change expands the approved age range for the OraQuick® HIV Self-Test to include individuals 14 years of age and older. Previously the test was approved for use in those 17 and older.
Received an award through the Rapid Response Partnership Vehicle (RRPV) for the development of a Marburg Virus Disease (MVD) rapid antigen test. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The initial contract award, valued at approximately $7.5 million over multiple years in the base period with potential value up to $11 million, funds the development to achieve FDA 510(k) clearance of a single-use lateral flow immunoassay intended for the qualitative detection of antigens from viruses within the Marburg virus genus.
Made significant progress in exiting our Risk Assessment testing business. We plan to continue to support our Risk Assessment customers and wind down remaining inventory during the first half of 2025.
Financial Guidance
The Company is guiding to Q1 2025 revenues of $27.5 million to $31.5 million. The Company anticipates Core revenues in Q1 2025 of $27 million to $31 million, which includes approximately $1 million of Risk Assessment testing revenues. The Company anticipates COVID-19 revenues in Q1 2025 of approximately $0.5 million.
Conference Call
The Company will host a conference call and audio webcast to discuss the Company's fourth quarter 2024 results and certain business developments, beginning today at 5 p.m. Eastern Time. The call will include prepared remarks by management and a question and answer session.
A webcast of the conference call will be available on the investor relations page of OTI's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OTI's website shortly after the call has ended and will be available for approximately 90 days. If a participant will be listen-only, they are encouraged to listen via the webcast.
For participants interested in asking a question during the conference call, please follow the link below to pre-register. After registering, you will be provided with your access details via email. It is recommended to dial in at least 15 minutes prior to the call start time.
OTI intends to use the Investor Relations Section of its website as a means of disclosing material non-public information (MNPI) and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor OTI's website in addition to following its press releases, SEC filings, public conference calls, presentations, and webcasts.
Financial Data (Unaudited)
For the Three Months Ended December 31,
For the Years Ended December 31,
2024
2023
2024
2023
Results of Operations
Net revenues
$
37,445
$
75,881
$
185,827
$
405,472
Cost of products and services sold
23,879
40,755
106,437
233,820
Gross profit
13,566
35,126
79,390
171,652
Operating expenses:
Research and development
6,087
6,991
26,047
33,728
Sales and marketing
6,992
6,906
30,986
36,319
General and administrative
12,905
14,005
46,215
58,191
Loss on impairments
—
3,326
4,392
10,829
Change in the estimated fair value of acquisition-related contingent consideration
—
—
—
(99
)
Total operating expenses
25,984
31,228
107,640
138,968
Operating income (loss)
(12,418
)
3,898
(28,250
)
32,684
Other income
2,911
16,822
12,249
23,574
Income (loss) before income taxes
(9,507
)
20,720
(16,001
)
56,258
Income tax expense
758
647
1,799
2,603
Loss on equity investment
(529
)
—
(1,700
)
—
Net income (loss)
$
(10,794
)
$
20,073
$
(19,500
)
$
53,655
Income (loss) per share:
Basic
$
(0.14
)
$
0.27
$
(0.26
)
$
0.73
Diluted
$
(0.14
)
$
0.27
$
(0.26
)
$
0.72
Weighted average shares outstanding:
Basic
74,597
73,499
74,434
73,348
Diluted
74,597
75,013
74,434
74,389
For the Three Months Ended December 31,
For the Years Ended December 31,
2024
2023
% Change
2024
2023
% Change
Consolidated Net Revenues
Diagnostics
$
18,768
$
17,219
9
%
$
75,917
$
73,694
3
%
Sample Management Solutions
14,809
13,044
14
51,046
54,274
(6
)
COVID-19 Diagnostics
950
41,617
(98
)
45,136
257,493
(82
)
Risk Assessment Testing
2,055
2,196
(6
)
8,354
9,736
(14
)
Other products and services
636
526
21
2,417
2,265
7
Molecular Services
13
907
(99
)
1,705
4,474
(62
)
COVID-19 Molecular Products
—
47
(100
)
36
286
(87
)
Net product and services revenues
37,231
75,556
(51
)
184,611
402,222
(54
)
Non-product and services revenues
214
325
(34
)
1,216
3,250
(63
)
Net revenues
$
37,445
$
75,881
(51)%
$
185,827
$
405,472
(54)%
Condensed Consolidated Balance Sheets (Unaudited)
December 31, 2024
December 31, 2023
Assets
Cash and cash equivalents
$
267,763
$
290,407
Accounts receivable, net
23,816
40,171
Inventories
34,197
47,614
Other current assets
7,444
8,267
Property, plant and equipment, net
45,105
45,420
Intangible assets, net
17,134
1,206
Goodwill
41,831
35,696
Investment in equity method investee
28,300
—
Other noncurrent assets
15,269
14,064
Total assets
$
480,859
$
482,845
Liabilities and Stockholders' Equity
Accounts payable
$
8,173
$
13,151
Deferred revenue
2,961
1,559
Other current liabilities
22,349
24,826
Other noncurrent liabilities
37,038
12,638
Stockholders' equity
410,338
430,671
Total liabilities and stockholders' equity
$
480,859
$
482,845
Additional Financial Data (Unaudited)
For the Years Ended December 31,
2024
2023
Capital expenditures
$
3,797
$
10,303
Proceeds from funding under government contract (1)
—
48,669
Depreciation and amortization
10,872
20,936
Stock-based compensation
11,920
10,729
Cash provided by operating activities
$
27,374
$
141,583
(1) Proceeds represent reimbursement for capital expenditures, engineering consulting costs, and guaranteed profit to cover project management costs.
Consolidated Statement of Cash Flows (Unaudited)
For the Years Ended December 31,
2024
2023
OPERATING ACTIVITIES:
Net (loss) income
$
(19,500
)
$
53,655
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Stock-based compensation
11,920
10,729
Depreciation and amortization
10,872
20,936
Loss on impairments
4,392
10,829
Other non-cash amortization
(564
)
3
Provision for credit losses
71
(462
)
Unrealized foreign currency gain
(263
)
103
Interest expense on finance leases
22
51
Loss on equity investment
1,700
—
Deferred income taxes
(657
)
102
Loss on sale of fixed assets
563
—
Change in the estimated fair value of acquisition-related contingent consideration
—
(99
)
Payment of acquisition-related contingent consideration
—
(19
)
Changes in assets and liabilities:
Accounts receivable
15,872
31,116
Inventories
13,096
48,228
Prepaid expenses and other assets
4,089
(2,499
)
Accounts payable
(7,577
)
(26,976
)
Deferred revenue
(219
)
(730
)
Accrued expenses and other liabilities
(6,443
)
(3,384
)
Net cash provided by operating activities
27,374
141,583
INVESTING ACTIVITIES:
Purchases of short-term investments
(53,244
)
(74,652
)
Investment in equity method investee
(30,000
)
—
Proceeds from maturities and redemptions of short-term investments
53,052
102,440
Purchases of property and equipment
(3,797
)
(5,802
)
Acquisition of business, net of cash acquired
(5,037
)
—
Purchase of property and equipment under government contracts
—
(4,501
)
Proceeds from funding under government contract (1)
—
48,669
Net cash (used in) provided by investing activities
(39,026
)
66,154
FINANCING ACTIVITIES:
Cash payments for lease liabilities
(842
)
(1,345
)
Proceeds from exercise of stock options
214
269
Payment of acquisition-related contingent consideration
—
(46
)
Repurchase of common stock
(3,548
)
(1,901
)
Net cash used in financing activities
(4,176
)
(3,023
)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH
(6,816
)
1,713
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
(22,644
)
206,427
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD
290,407
83,980
CASH AND CASH EQUIVALENTS, END OF PERIOD
$
267,763
$
290,407
About OraSure Technologies
OraSure Technologies, Inc. ("OraSure" and "OTI") transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure's portfolio of products is sold globally to clinical laboratories, hospitals, physician's offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.
About Marburg Virus Disease (MVD) rapid antigen test
The Marburg Virus Disease (MVD) rapid antigen test project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Number: 75A50123D00005, and the Project Identifier is RRPV-24-06-DxR2-007 (OraSure).
Forward Looking Statements
This press release contains certain forward-looking statements, including with respect to products, product candidate development and manufacturing activities, regulatory submissions and authorizations, revenue growth and guidance, expected revenue from government orders, cost savings, cash flow, increasing margins and other matters. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: our ability to satisfy customer demand; ability to reduce our spending rate, capitalize on manufacturing efficiencies and drive profitable growth; ability to market and sell products, whether through our internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; ability to manufacture or have manufactured products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the FDA or other regulators; the demand for our COVID-19 testing products; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; impact of replacing distributors; inventory levels at distributors and other customers; our ability to achieve its financial and strategic objectives and increase our revenues, including the ability to expand international sales and the ability to continue to reduce costs; impact of competitors, competing products and technology changes; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of our products; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; impact of contracting with the U.S. government; impact of negative economic conditions; ability to achieve and maintain sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of our stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; cybersecurity breaches or other attacks involving our systems or those of our third-party contractors and IT service providers, suppliers and customers; the impact of terrorist attacks, civil unrest, hostilities and war; and general political, business and economic conditions, including inflationary pressures, the imposition of tariffs and banking stability. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2023, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.
Statement Regarding Use of Non-GAAP Financial Measures
In this press release, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures, including non-GAAP gross margin, non-GAAP gross profit, non-GAAP net income (loss), non-GAAP operating income (loss), and non-GAAP earnings (loss) per share. Management believes that presentation of operating results using these non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods, while excluding certain expenses that may not be indicative of the Company's recurring core business operating results. In addition, management believes these non-GAAP financial measures are useful to investors both because they (1) allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) are used by OraSure's institutional investors and the analysis community to help them analyze the health of OraSure's business. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the schedules below and a description of the adjustments made to the GAAP financial measures is included at the end of the schedules.
The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Further, non-GAAP financial measures, even if similarly titled, may not be calculated in the same manner by all companies, and therefore should not be compared.
OraSure Technologies GAAP to Non-GAAP Reconciliation ($ in 000's)
For the Three Months Ended December 31,
For the Years Ended December 31,
2024
2023
2024
2023
Revenue
$
37,445
$
75,881
$
185,827
$
405,472
GAAP Cost of products and services sold
23,879
40,755
106,437
233,820
GAAP Gross Margin
36.2
%
46.3
%
42.7
%
42.3
%
Stock compensation
195
138
734
564
Amortization of acquisition-related intangible assets
—
—
—
396
Reduction in workforce severance
239
—
1,366
369
Transformation related expenses
—
—
—
281
Inventory reserve for product line discontinuance
1,000
—
1,000
—
Non-GAAP Cost of Goods Sold
22,445
40,617
103,337
232,210
Non-GAAP Gross Margin
40.1
%
46.5
%
44.4
%
42.7
%
GAAP Operating Income (Loss)
(12,418
)
3,898
(28,250
)
32,684
Stock compensation
2,741
3,127
11,919
10,729
Amortization of acquisition-related intangible assets
103
150
279
1,549
Reduction in workforce severance
849
—
3,258
3,265
Inventory reserve for product line discontinuance
1,000
—
1,000
—
Loss on impairment
—
3,326
4,392
10,829
Transformation related expenses
—
—
—
707
Transaction costs
980
650
980
650
Government grant accounting
—
—
—
2,036
Change in fair value of acquisition-related contingent consideration
—
—
—
(99
)
Non-GAAP Operating Income (Loss)
(6,745
)
11,151
(6,422
)
62,350
GAAP Net Income (Loss)
(10,794
)
20,073
$
(19,500
)
53,655
Stock compensation
2,741
3,127
11,919
10,729
Amortization of acquisition-related intangible assets
103
150
279
1,549
Reduction in workforce severance
849
—
3,258
3,264
Inventory reserve for product line discontinuance
1,000
—
1,000
—
Loss on impairment
—
3,326
4,392
10,829
Transformation related expenses
—
—
—
707
Transaction costs
980
650
980
650
Change in fair value of acquisition-related contingent consideration
—
—
—
(99
)
Loss on equity investment
529
—
1,700
—
Additional profit from government contract
—
(12,802
)
—
(12,802
)
Tax effect of non-GAAP adjustments
362
(1,003
)
(85
)
(2,171
)
Non-GAAP Net Income (Loss)
$
(4,230
)
$
13,521
$
3,943
$
66,311
GAAP Earnings (Loss) Per Share:
$
(0.14
)
$
0.27
$
(0.26
)
$
0.72
Non-GAAP Earnings (Loss) Per Share:
$
(0.06
)
$
0.18
$
0.05
$
0.89
Diluted Shares Outstanding
74,597
75,013
74,434
74,389
Diluted Shares Outstanding Used For Computing Non-GAAP Earnings (Loss) Per Share
74,597
75,013
75,329
74,389
The following is a description of the adjustments made to GAAP financial measures:
Stock Compensation: non-cash equity-based compensation provided to OraSure employees and directors
Amortization of acquisition-related intangible assets: represents recurring amortization charges resulting from the acquisition of intangible assets associated with our business combinations
Reduction in workforce severance: termination benefits associated with the Company's workforce reduction associated with certain business events
Inventory reserve for product line discontinuance: represents the write down of inventory associated with the risk assessment line of business that is discontinued
Loss on impairment: charges related to the write down of Company's intangibles, PP&E, or leased assets
Transformation related expenses: transitory costs such as consulting and professional fees related to transformation initiatives
Government contract accounting: As required under International Accounting Standard Board IAS 20, Accounting for Government Contracts and Disclosure of Government Assistance, our operating expenses associated with the Department of Defense expansion contract are reflected in operating expenses with offsetting reimbursement reflected in other income
Change in fair value of acquisition-related contingent consideration: changes in the fair value of contingent consideration liability associated with estimate changes in reaching contingent consideration metrics
Loss on equity investment: we have excluded our proportionate share of our equity method investee's net loss as we do not have direct control over the investee's operations or resulting revenue and expenses
Tax impact associated with non-GAAP adjustments – tax expense/(benefit) due to non-GAAP adjustments
